CLINICAL TRIAL: ACTG 219: PEDIATRIC LATE OUTCOMES (AIDS)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 有必要更好地评估对儿童实施的各种抗艾滋病毒疗法的积极和消极的近期后果。这项研究旨在收集前瞻性的纵向数据，以确定1)与艾滋病毒疾病进展、治疗或预防性干预有关的晚期结果和后果，和/或艾滋病毒疾病和治疗的相互作用，以及2)围产期接受治疗但未感染的婴儿的晚期治疗效果。数据将包括病史、生活质量评估、体检、神经认知测试、临床和实验室评估、发病率和死亡率。这项研究将持续到孩子21岁生日或失去随访。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is a need to better assess both positive and negative late consequences of the various anti-HIV therapies administered to children. This study is designed to collect prospective, longitudinal data to identify 1)late outcomes and consequences related to HIV disease progression, treatment or prophylactic intervention, and/or interaction of HIV disease and therapy and 2) late treatment effects among perinatally treated infants proven to be uninfected. Data will include history, quality of life assessment, physical exam, neurocognitive testing, clinical and laboratory evaluations, morbidity, and mortality. The study will last until the child reaches his/her 21st birthday or is lost to follow-up.